Supporting your immuno-onco drug discovery programs from hit identification to candidate selection!

The use of immunotherapies in oncology has drastically changed the way of treating cancer, providing innovative and efficient therapeutic solutions. Currently, tremendous R&D efforts are done in immuno-oncology to discover new targets and develop new drugs. In that context, the use of relevant and robust assays to predict therapeutic efficiencies has become a key for drug discovery programs.

Oncodesign develops a broad range of solutions to support your drug discovery projects in immuno-oncology. We can provide solutions on a stand alone basis or through an integrated drug discovery package - from hit identification to candidate selection.

Based on human immune material for in vitro/ex vivo phenotypic assays and on advanced preclinical models – syngeneic or humanized - for in vivo assays, our scientists help you to assess your compound efficiency in routine or customized assays.

Key learning objectives:

• How Oncodesign can help you to support your drug discovery project at each step of your pre-clinical development.
• Vitro/Vivo assays developed by Oncodesign for routine assessment of molecules.
• Tailored-made solutions: Case studies